Offered exclusively by Vasomedical. EECP therapy is a safe, non-invasive, outpatient treatment option for patients suffering from ischemic heart diseases such as angina and heart failure. EECP therapy has helped 1000's of patients. In fact, clinical studies show, over 75% of patients benefit from EECP therapy and sustain improvement up to three years post- treatment.

Update Share

About Vasomedical Report

VasoMedical, Inc. is a global leader in non-invasive healthcare solutions and products with the corporate office and manufacturing in Plainview, New York. We also have manufacturing facilities in China. Our proprietary core product line of Enhanced External Counterpulsation (EECP) Therapy systems is the leading product in the non-invasive treatment of cardiovascular disease.

Employment Opportunities Report

Exploring exciting opportunities to improve the delivery of business and healthcare technology globally. Vaso Corporation ("Vaso" or the "Company"), formerly Vasomedical, Inc., is a medical technology company with experience and expertise that crosses diverse product and service categories, including noninvasive monitoring and therapeutic devices, diagnostic imaging equipment, and information technology for enterprises and clinical customers.

EECP® Systems Report

Delivering A New Quiet Air of Confidence - Backed by years of clinical research and numerous published data, Our EECP Therapy System incorporates the proven performance of EECP technology in a sleek and self-contained unit that is easy to use and fosters patient confidence, comfort and compliance. The LumenairTM EECP Therapy System combines proven medical technology with enhanced styling in a compact model that's easy to operate. Our latest improvement has allowed the Lumenair to work even more quietly.

EECP® Advantage Report

Now, all the answers are here! Introducing the VasoMedical AdvantageTM - A Total Product Offering. The VasoMedical AdvantageTM is designed to ensure the clinical and economic success of our customers' EECP Therapy Programs. VasoMedical is the ONLY company that offers the Enhanced External Counter Pulsation technology (EECP).

Treatment Centers Report

Cardiovascular disease (CVD) remains the leading cause of death in the United States, responsible for 840,768 deaths (635,260 cardiac) in 2016. From 2006 to 2016, the US death rate from CVD decreased by 18.6% and from coronary heart disease by 31.8%. In the United States in 2019, coronary events were expected to occur in about 1,055,000 individuals, including 720,000 new and 335,000 recurrent coronary events.

Be the first to review Vasomedical.

Write a Review